Genmab AS (GMAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Genmab AS (GMAB) has a cash flow conversion efficiency ratio of 0.051x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($300.34 Million) by net assets ($5.83 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GMAB net asset quality score to measure how much of total assets are equity-financed.
Genmab AS - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Genmab AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Genmab AS to evaluate the quality of earnings relative to operating cash generation.
Genmab AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genmab AS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Millicom International Cellular SA
NASDAQ:TIGO
|
0.195x |
|
Samsung Fire & Marine Insurance
KO:000810
|
0.080x |
|
Hua Xia Bank Co Ltd
SHG:600015
|
-0.089x |
|
Cholamandalam Investment and Finance Company Limited
NSE:CHOLAFIN
|
-1.249x |
|
EVE Energy
SHE:300014
|
0.063x |
|
News Corporation
AU:NWSLV
|
0.055x |
|
mBank SA
WAR:MBK
|
-0.739x |
|
KGHM Polska Miedz SA
WAR:KGH
|
0.041x |
Annual Cash Flow Conversion Efficiency for Genmab AS (2002–2025)
The table below shows the annual cash flow conversion efficiency of Genmab AS from 2002 to 2025. For the full company profile with market capitalisation and key ratios, see Genmab AS market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.83 Billion | $1.19 Billion | 0.203x | -3.92% |
| 2024-12-31 | $36.70 Billion | $7.77 Billion | 0.212x | -9.30% |
| 2023-12-31 | $31.61 Billion | $7.38 Billion | 0.233x | +62.82% |
| 2022-12-31 | $27.28 Billion | $3.91 Billion | 0.143x | +42.85% |
| 2021-12-31 | $22.20 Billion | $2.23 Billion | 0.100x | -70.16% |
| 2020-12-31 | $19.12 Billion | $6.43 Billion | 0.336x | +256.43% |
| 2019-12-31 | $14.05 Billion | $1.33 Billion | 0.094x | -25.45% |
| 2018-12-31 | $8.01 Billion | $1.01 Billion | 0.127x | -50.02% |
| 2017-12-31 | $6.27 Billion | $1.59 Billion | 0.253x | +273.12% |
| 2016-12-31 | $4.83 Billion | $327.72 Million | 0.068x | -23.99% |
| 2015-12-31 | $3.49 Billion | $311.45 Million | 0.089x | +36.87% |
| 2014-12-31 | $2.03 Billion | $132.67 Million | 0.065x | +133.63% |
| 2013-12-31 | $659.52 Million | $-128.00 Million | -0.194x | -204.86% |
| 2012-12-31 | $383.19 Million | $70.92 Million | 0.185x | +120.59% |
| 2011-12-31 | $486.42 Million | $-437.23 Million | -0.899x | -462.02% |
| 2010-12-31 | $1.08 Billion | $268.17 Million | 0.248x | +156.50% |
| 2009-12-31 | $1.30 Billion | $-570.06 Million | -0.439x | -87.36% |
| 2008-12-31 | $2.19 Billion | $-513.33 Million | -0.235x | -233.68% |
| 2007-12-31 | $2.88 Billion | $505.90 Million | 0.175x | +174.30% |
| 2006-12-31 | $1.61 Billion | $-379.62 Million | -0.236x | -26.62% |
| 2005-12-31 | $1.12 Billion | $-208.64 Million | -0.186x | +40.10% |
| 2004-12-31 | $1.18 Billion | $-367.70 Million | -0.311x | -11.87% |
| 2003-12-31 | $1.09 Billion | $-302.36 Million | -0.278x | -26.30% |
| 2002-12-31 | $1.40 Billion | $-308.32 Million | -0.220x | -- |
About Genmab AS
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervi… Read more